ROS sensitize glioma cells to chemotherapeutic agents (Sharma et al., 2007; Dixit et al., 2009), while TIGAR protects cells from ROS-related apoptosis (Sinha et al., 2013). This evidence concerns the gene TIGAR and central nervous system cancer.